Michael Crackower, Chief Scientific Officer at Ventus Therapeutics, and PhD researcher Jason Burch dive into the future of drug discovery. They unveil the ReSOLVE platform, designed to quickly iterate small molecular compounds for therapeutic use. The duo discusses the importance of water dynamics in protein interactions, machine learning's role in drug design, and their strides in targeting NLRP3 for neurodegenerative diseases. With groundbreaking data and a push to enter clinical trials, they highlight the rapid progress made from concept to investigational new drug.
